$0.5175
-0.0286-5.24%
Ult. Agg.: Oct 23, 7:57 PM
Karyopharm Therapeutics (KPTI) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Karyopharm Therapeutics (KPTI) ha pubblicato l'ultima guidance il agosto 13, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $130M - $150M per il periodo.
Rispetto alle previsioni precedenti, Karyopharm Therapeutics ha modificato le sue previsioni di fatturato da un intervallo precedente di .
Karyopharm Therapeutics ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il Karyopharm Therapeutics. 24
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.42 | $-1.44 | $-2.10 | $-3.27 |
| Actual | $-2.32 | $-1.24 | $-2.23 | $-3.82 |
| Surprise | -63.4% | +13.9% | -6.19% | -16.8% |
| Revenue | ||||
| Estimate | $32.1M | $31.9M | $33.2M | $42.4M |
| Actual | $33.4M | $35.1M | $34.1M | $44.0M |
| Surprise | +4.21% | +9.91% | +2.77% | +3.86% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.28 | $-1.18 | $-1.14 | $-1.01 |
| Revenue | ||||
| Consensus | $33.4M | $34.3M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-2.32 | $-1.42 | -63.4 % |
| Q1 | May 14, 2026 | $-1.24 | $-1.44 | 13.9 % |
| Q4 | Feb 12, 2026 | $-2.23 | $-2.10 | -6.19 % |
| Q3 | Nov 3, 2025 | $-3.82 | $-3.27 | -16.8 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $33.43M | $32.08M | 4.21 % |
| Q1 | May 14, 2026 | $35.07M | $31.91M | 9.91 % |
| Q4 | Feb 12, 2026 | $34.08M | $33.16M | 2.77 % |
| Q3 | Nov 3, 2025 | $44.00M | $42.37M | 3.86 % |